Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Contact phone
180.096.85570
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Melanoma
Webform